A Systematic Approach Towards UPLC® Method Development

Importance of the Topic

Method development in high‐performance liquid chromatography (HPLC) and ultra‐performance liquid chromatography (UPLC) is critical for timely, robust, and high-resolution analysis in pharmaceutical and industrial laboratories. The need to streamline workflows, reduce analysis time, and address diverse sample matrices has driven advances in column technology, systematic screening protocols, and automated method design.

Objectives and Study Overview

This work presents a structured UPLC method development strategy that integrates stationary phase selection, organic modifier variation, and mobile phase pH optimization with automated software tools. A Quality by Design (QbD) framework guides the systematic screening and Design of Experiments, illustrated by a case study on mirtazapine and related impurities.

Methodology and Instrumentation

• Systematic screening evaluated four column chemistries (CSH C18, CSH Phenyl-Hexyl, CSH Fluoro-Phenyl, HSS C18 SB), two organic solvents (acetonitrile, methanol) and two pH conditions (≈3, ≈10).
• Automated workflows used Waters ACQUITY UPLC H-Class with Quaternary Solvent Manager and Column Manager, combined with Fusion AE software and Empower 2 CDS for experimental design and data processing.
• Sub-2 µm columns (1.7–1.8 µm, 2.1×50 mm) were operated with 2–6.5 min gradients, 0.2–0.7 mL/min flow, 30–45 °C, and PDA/SQD detection.

Main Results and Discussion

• CSH columns exhibited broad pH stability (1–11), superior peak shape and consistent performance in low ionic strength mobile phases compared to conventional phases.
• Methanol as a weaker elution solvent increased retention and altered selectivity; acetonitrile provided faster elution and better peak symmetry.
• Mobile phase pH critically influenced analyte ionization: neutral forms showed higher retention, enabling pH‐driven selectivity tuning.
• Automated screening and DoE optimization identified optimal conditions (CSH C18, acetonitrile, pH 10.6, 5–78% B in 6.5 min, 0.7 mL/min, 45 °C) for baseline separation of mirtazapine and six impurities within one day.

Benefits and Practical Applications

• Method development time reduced up to 4× using sub-2 µm columns and automated screening.
• Enhanced method robustness and transferability between HPLC and UPLC through matched chemistries (XBridge/ACQUITY BEH, HSS/CSH).
• Improved sensitivity and peak shape in low ionic strength mobile phases compatible with mass spectrometry.
• Alignment with regulatory QbD guidelines facilitates method validation, robustness studies, and lifecycle management.

Future Trends and Opportunities

Emerging column technologies (core-shell, novel hybrids), high-throughput and multiplexed platforms, sustainable solvents, and machine learning–driven method design are poised to further accelerate robust chromatographic development, delivering greener, faster, and more precise analyses.

Conclusion

A systematic UPLC method development approach that combines targeted screening of stationary phases, solvents and pH with automated DoE optimization delivers rapid, high-performance, and regulatory-compliant separations, substantially reducing resource and time investments.

Reference

• Marchand DH, et al. J Chromatogr A. 2003;1015:53-64.